Elucid has raised $55 Million in New Series D Funding

According to filings with the U.S. Securities and Exchange Commission, Elucid has raised $55,000,000.00 in new Series D funding. The federal securities law requires the notice to be filed by...

Craig Etkin

October 6, 2026 2 Min Read

6 0

According to filings with the U.S. Securities and Exchange Commission, Elucid has raised $55,000,000.00 in new Series D funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: IAG Capital Partners and Elevage Medical Technologies

About Elucid
Elucid is a Boston-based medical technology company that develops AI-powered cardiovascular imaging software to help physicians visualize lesion-level plaque composition and see invisible features of cardiovascular risk. Drawing on ground truth histology and clinically validated algorithms, Elucids platform is designed to give a more precise view of atherosclerosis the root cause of cardiovascular diseaseso clinicians can deliver CCTA-guided, personalized care and optimize treatment decisions based on actual disease rather than population-based risk. The companys flagship PlaqueIQ image analysis software focuses on quantifying and characterizing plaque to support precision diagnosis and tailored therapy for patients with cardiovascular disease. Positioned as a pioneer in AI medical technology for cardiology, Elucid emphasizes bringing the level of precision seen in oncology into cardiovascular care, strengthening its role in advancing personalized, lesion-level cardiovascular management. The firm highlights its commitment to helping physicians better understand cardiovascular disease mechanisms and improve patient outcomes through advanced imaging analysis and decision-support tools.

To learn more, visit https://elucid.com/
Linkedin: https://www.linkedin.com/company/elucid-inc/

Contact:
Kelly Huang, Chief Executive Officer
https://www.linkedin.com/in/kelly-huang-phd